- Home
- ODD vs PTGX Comparison
ODD vs PTGX Comparison
Compare ODD & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- PTGX
- Stock Information
- Founded
- ODD 2018
- PTGX 2006
- Country
- ODD Israel
- PTGX United States
- Employees
- ODD N/A
- PTGX N/A
- Industry
- ODD
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- ODD
- PTGX Health Care
- Exchange
- ODD Nasdaq
- PTGX Nasdaq
- Market Cap
- ODD 2.4B
- PTGX 2.7B
- IPO Year
- ODD 2023
- PTGX 2016
- Fundamental
- Price
- ODD $44.87
- PTGX $36.82
- Analyst Decision
- ODD Buy
- PTGX Strong Buy
- Analyst Count
- ODD 8
- PTGX 8
- Target Price
- ODD $53.13
- PTGX $54.63
- AVG Volume (30 Days)
- ODD 371.5K
- PTGX 660.4K
- Earning Date
- ODD 03-04-2025
- PTGX 02-25-2025
- Dividend Yield
- ODD N/A
- PTGX N/A
- EPS Growth
- ODD 80.44
- PTGX N/A
- EPS
- ODD 1.64
- PTGX 2.68
- Revenue
- ODD $620,646,000.00
- PTGX $323,795,000.00
- Revenue This Year
- ODD $27.67
- PTGX $441.08
- Revenue Next Year
- ODD $20.12
- PTGX N/A
- P/E Ratio
- ODD $27.30
- PTGX $13.72
- Revenue Growth
- ODD 29.59
- PTGX 125.73
- 52 Week Low
- ODD $30.34
- PTGX $23.89
- 52 Week High
- ODD $51.00
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- ODD 53.76
- PTGX 39.62
- Support Level
- ODD $41.69
- PTGX $35.03
- Resistance Level
- ODD $44.37
- PTGX $40.07
- Average True Range (ATR)
- ODD 1.90
- PTGX 1.56
- MACD
- ODD 0.08
- PTGX -0.04
- Stochastic Oscillator
- ODD 84.90
- PTGX 34.89
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.